Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

By |2021-03-29T20:24:19-04:00March 30th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties.  This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...